Home Medizin PharmaKure kündigt epigenetische Zusammenarbeit mit der Sheffield Hallam University an, um die Mechanismen der Alzheimer-Krankheit zu verstehen

PharmaKure kündigt epigenetische Zusammenarbeit mit der Sheffield Hallam University an, um die Mechanismen der Alzheimer-Krankheit zu verstehen

von NFI Redaktion

PharmaKure, a clinical stage pharmaceutical company developing precision medicine for Alzheimer’s disease and other neurodegenerative disorders, announced a new epigenetic collaboration with Sheffield Hallam University today. This partnership will focus on „gene-based environmental biomarkers,“ known as epigenetic markers, to calculate risk assessments for Alzheimer’s disease. By combining ALZmetrixTM, PharmaKure’s blood-based biomarker, with the current Alzheimer’s diagnostics, the efficacy will be enhanced.

The joint study between Sheffield Hallam University and PharmaKure aims to gain a better understanding of Alzheimer’s disease (AD) in order to identify those at higher risk of developing the disease and enable the delivery of appropriate interventions much earlier in the disease pathology.

„We have been working on the relationship between environmental exposures and brain disorders.“ Professor Reynolds has published over 300 papers on neurotransmitter system pathologies involved in psychiatric disorders, and is now focusing on epigenetic impacts on neurodisorders.“‚

Professor Gavin Reynolds, Research Centre for Biomolecular Sciences, Sheffield Hallam University

Gavin adds, „Our genes are encoded in our DNA, but epigenetics explores how the cell turns genes on and off depending on different environmental influences such as aging, stress, trauma, etc. We aim to identify abnormal epigenetic changes associated with brain disorders, which can be altered with medications.“

Dr. Helene Fachim, Neuroscientist, PharmaKure

Helen further explains, „We want to utilize these epigenetic approaches to better comprehend AD, so we can assess an individual’s risk of developing it. Then we could take preventive action or administer AD medications earlier in life when they are more effective.“

AD is a multifactorial disease, and it is known that environmental factors can play a significant role in its onset. The main hypothesis of the study is that there is differential methylation at certain target genes related to AD compared to non-AD controls. If this hypothesis proves true, PharmaKure can begin validating an epigenetic predictive risk score for cognitive impairment and AD.

„We are very positive and excited about this new epigenetic collaboration and believe that the convergence of science and industry is the best way to achieve our goals. We look forward to sharing key findings in the near future.“

Dr. Farid Khan, CEO, PharmaKure.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.